

Medicare SSP – ACO Measures

Note: **Blue letters = proposed new measure; Red letters = measure proposed for replacement or deletion**

ACO #	Measure title	NQF #	Measure steward	Method of data submission	Pediatric	Commercial or Medicaid Measure	#	Preliminary Recommendations
Domain: patient/caregiver experience								
ACO-1	CAHPS: Getting timely care, appointments, and information	0005	AHRQ	Survey				
ACO-2	CAHPS: How well your providers communicate	0005	AHRQ	Survey				
ACO-3	CAHPS: Patients' rating of provider	0005	AHRQ	Survey				
ACO-4	CAHPS: Access to specialists	N/A	CMS	Survey				
ACO-5	CAHPS: Health promotion and education	N/A	CMS	Survey				
ACO-6	CAHPS: Shared decision making	N/A	CMS	Survey				
ACO-7	CAHPS: Health status/functional status	N/A	CMS	Survey				
ACO-X	CAHPS: Stewardship of Patient Resources	N/A	CMS	Survey				
Domain: care coordination/patient safety								
ACO-8	Risk standardized all condition readmission (new version to be released Spring 2014)	1789 (adapted)	CMS	Claims			3	

ACO-9	Ambulatory Sensitive conditions admissions: chronic obstructive pulmonary disease (COPD) or asthma in older adults	0275	AHRQ, PQI-5	Claims				
ACO-X	All-cause unplanned admission for DM		AHRQ, PQI-1?	Claims				
ACO-X	All-cause unplanned admission for heart failure		AHRQ, PQI-?	Claims				
ACO-X	All-cause unplanned admission for multiple chronic conditions		AHRQ, PQI-92?	Claims				
ACO-10	Ambulatory sensitive conditions admissions: heart failure (HF)	0277	AHRQ	Claims				
ACO-11	Percent of primary care physicians who successfully qualify for an EHR program incentive payment	NA	CMS	Claims and EHR Incentive Program Reporting				
ACO-XX	Percent of primary care physicians who successfully meet meaningful use requirements	NA	CMS	Claims and EHR Incentive Program Reporting				
ACO-X	30-day all cause SNF readmission measure							

CARE-1 (ACO-12)	Medication reconciliation	0097	AMA-PCPI/ NCQA	QMAT/WI				
CARE-X (ACO-XX)	Documentation of current medications in the medical record		PQRS/EHR					
CARE-2 (ACO-13)	Falls: screening for future fall risk	0101	AMA-PCPI/ NCQA	QMAT/WI				
Domain: preventive health								
PREV-5 (ACO-20)	Breast cancer screening	NA	NCQA	QMAT/WI			4	
PREV-6 (ACO-19)	Colorectal cancer screening	0034	NCQA	QMAT/WI			2	
PREV-7 (ACO-14)	Preventive care and screening: influenza immunization	0041	AMA/PCPI	QMAT/WI			1	
PREV-8 (ACO-15)	Pneumonia vaccination status for older adults	0043	NCQA	QMAT/WI				
PREV-9 (ACO-16)	Preventive care and screening: body mass index screening and follow-up	0421	QIP	QMAT/WI				
PREV-10 (ACO-17)	Preventive care and screening: tobacco use: screening and cessation intervention	0028	AMA/PCPI	QMAT/WI			1	
PREV-11 (ACO-21)	Preventive care and screening: screening for high blood pressure and follow-up documented	NA	QIP	QMAT/WI				
PREV-12 (ACO-18)	Preventive care and screening: screening for clinical depression and follow-up plan	0418	QIP	QMAT/WI				

	Depression readmission at 12 months							
Domain: at-risk population								
Diabetes								
DM-2 (ACO-27)	Diabetes: hemoglobin A1c poor control (>9%)	0059	NCQA	QMAT/WI			2	
DM-X (ACO-41)	Diabetes foot exam							
DM-X (ACO-42)	Diabetes eye exam		NCQA/HEDIS				4	
DM-13 through 17 (ACO-22 through 26)	Diabetes all-or-nothing composite: <ul style="list-style-type: none"> ▪High blood pressure control ▪Low density lipoprotein (LDL-C) control ▪Hemoglobin A1c control (<8%) ▪Daily aspirin or antiplatelet medication use for patients with diabetes and ischemic vascular disease ▪Tobacco non-use 	0729	MCM	QMAT/WI				
Hypertension								
HTN-2 (ACO-28)	Controlling high blood pressure	0018	NCQA	QMAT/WI			2	
Ischemic vascular disease								

IVD-1 (ACO-29)	Ischemic vascular disease: complete lipid panel and LDL control	0075 (73?)	NCQA	QMAT/WI			1	
IVD-2 (ACO-30)	Ischemic vascular disease: use of aspirin of another antithrombotic	0068	NCQA	QMAT/WI			1	
Heart failure								
HF-6 (ACO-31)	Heart failure: beta-blocker therapy for left ventricular systolic dysfunction	0083	AMA/PCPI/ACC/AHA/AMA	QMAT/WI			1	
Coronary artery disease								
CAD-2 (ACO-32)	Coronary artery disease all-or-nothing composite: Lipid Control	0074	AMA/PCPI/ACC/AHA/AMA	QMAT/WI			1	
CAD-7 (ACO-33)	Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB) therapy—diabetes or left ventricular systolic dysfunction	0066	AMA/PCPI/ACC/AHA/AMA	QMAT/WI			2	
CAD-X (ACO-43)	Antiplatelet therapy						1?	
CAD-X (ACO-44)	Symptom management – CAD pt seen within 12 months for angina symptoms							
CAD-X (ACO-45)	Beta blocker therapy prior MI or LVEF	0070						

Version 2 - 6/22/14

*AHRQ = Agency for Healthcare Research and Quality, ACC = American College of Cardiology, AHA = AmericanHeart Association, AMA = American Medical Association, MCM = Minnesota Community Measurement, NCQA = National Committee on Quality Assurance, PCPI = Physician Consortium for Performance Improvement, QIP = Quality Insights of Pennsylvania.

***Italics* = Payer appears to use same measure, though potentially with different technical specifications

Commercial Measures not part of Medicare ACO Measure Set

ACO #	Measure title	NQF #	Measure steward	Method of data submission	Pediatric	Commercial or Medicaid Measure	#	Preliminary recommendation
Domain: access and availability of care								
	Children and adolescents access to primary care practitioners		NCQA/HEDIS		P		2	
	Adults access to preventive/ ambulatory health services						1	
Domain: Care coordination/Patient safety								
	% of prescribers that use e-prescribing						1	
	Adverse event rate – outpatient procedures						1	
	Annual % of asthma patients (ages 2-20) with one or more asthma-related emergency department visits				P		1	
	Post-Admission Follow-up: Percentage of adults w/ inpatient “medicine” admissions with post-admission follow-up within 7 days of discharge						1	
	Ambulatory Sensitive		Informed by PQI				1	

	Admissions							
Domain: preventive health								
	Cervical cancer screening		NCQA/HEDIS				4	
	Chlamydia screening in women		NCQA				2	
	Lead screening in children				P		1	
	Adolescent well-care visits		NCQA/HEDIS		P		1	
	Developmental screening in the first three years of life. Three age breakouts (ages 1, 2, and 3)				P		1	
	Well-child visits in the first 15 months of life				P		3	
	Well-child visits in the third, fourth, fifth and sixth years of life				P		3	
	Annual dental visit				P		1	
	Childhood immunizations DTaP and IPV				P		1	
	Childhood immunizations MMR		NCQA/HEDIS		P		1	
	Childhood immunizations VZV		NCQA/HEDIS		P		1	
	Adolescent immunizations Tdap/TD and meningococcal				P		1	

	Adolescent female immunizations HPV				P		1	
	Prenatal care		NCQA				2	
	Post-partum care						1	
	Adult BMI assessment						1	
Domain: at-risk population								
Asthma								
	Use of appropriate medication for people with asthma		NCQA/HEDIS/NQF		P/A		5	
	Disease modifying anti-rheumatic drug therapy for rheumatoid arthritis		NCQA/HEDIS/NQF				3	
CAD								
	Persistence of Beta blocker therapy after a heart attack	1528?	NCQA/HEDIS				4	
	Lipid lowering drug for LDL>30						1	
	ACE-I/ARB: Persistent use with lab monitoring		NCQA/HEDIS				3	
	Post-MI use of ACE-I/ARB w/ h/o HTN, DM, or HF		NCQA/HEDIS				2	
	Drug-eluting stent: antiplatelet therapy						1	
Cancer								
	Colorectal cancer: follow-up after treatment						1	
COPD								

	Pharmacotherapy management of COPD exacerbation		NCQA/HEDIS				2	
	Use of spirometry testing in the assessment and diagnosis of COPD						1	
Diabetes								
	Diabetes treatment						1	
	Diabetes: medical attention for nephropathy						1	
	Diabetes: A1C testing		NCQA/HEDIS				3	
	Diabetes: A1C testing, pediatric						1	
	Diabetes kidney disease monitoring/urine protein screening		NCQA/HEDIS				2	
	Comprehensive diabetes care						2	
	Diabetes: annual lipid profile		NCQA/HEDIS				2	
	Diabetes: LDL=>100 & lipid lowering agent use						1	
Epilepsy								
	Anticonvulsants: Persistent use with lab monitoring		NCQA/HEDIS				3	
	Carbamazepine: Persistent use with lab monitoring						2	

	Phenobarbital: Persistent use with lab monitoring						2	
	Phenytoin: Persistent use with lab monitoring						2	
	Valproic acid: Persistent use with lab monitoring						2	
Heart failure								
	Heart failure: beta- blocker therapy		ACC/AHA				1	
	Digoxin: Persistent use with lab monitoring		NCQA/HEDIS				3	
Hypertension (HTN)								
	HTN: Serum creatinine testing						1	
	Diuretics Persistent use with lab monitoring		NCQA/HEDIS				3	
Ischemic stroke								
	Warfarin: PT/INR monitoring						1	
Ischemic vascular disease (IVD)								
	MI, CABG, PCI or IVD with complete lipid profile						2	
	LDL \geq 100 and treated with lipid lowering agent, or LDL $<$ 100						1	
	LDL-C screening for patients with cardiovascular conditions		NCQA/HEDIS				1	

Low Back Pain							
	Use of imaging studies for low back pain		NCQA/HEDIS/NQF				2
Migraine							
	Migraine: Frequent use of acute meds/ receiving prophylactic meds						1
Osteoporosis							
	Osteoporosis management in women who had a fracture		NCQA/HEDIS/NQF				4
Otitis Media with Effusion							
	Tympanostomy tube insertion: pediatric hearing test						1
Any Diagnosis							
	Medication Adherence among members 81 years and older						1
Domain: Behavioral Health (BH)							
ADHD							
	Follow-up care for children prescribed ADHD medication		NCQA/HEDIS/NQF				2
Depression							
	Antidepressant medication management (acute or continuation?)		NCQA/HEDIS/NQF				2
Any Diagnosis							

	Percentage of adults given a new psychiatric diagnoses, and medication, by a PCP who received a follow-up visit within 30 days						1	
Domain: acute care								
	Avoidance of antibiotic treatment in adults with acute bronchitis		NCQA/HEDIS/NQF				2	
	Appropriate testing for children with pharyngitis		NCQA/HEDIS/NQF		P		2	
	Appropriate treatment for children with upper respiratory infection		NCQA/HEDIS/NQF		P		3	
Domain: Obstetrics								
	Cesarean section rate in singleton low risk deliveries						1	
	Episiotomy in vaginal deliveries						1	
Resource efficiency								
	Bed days/1000						1	
	ER: ambulatory visits /1k members				C, A		2	
	Potentially avoidable ER rate		Custom				1	
	Generic dispensing/ substitution		Custom?				2	

Note:

- 1) Did not include Cigna “Evidence-based measures”
- 2) One payer appears to track and reward NCQA PCMH recognition or NCQA Bridges to Excellence Condition Specific Recognition Programs
- 3) EOC efficiency index – cost comparison of complete or full year episodes of care against an adjusted average by episode treatment group.